Subvenite is a drug owned by Owp Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 29, 2040. Details of Subvenite's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11596634 | Lamotrigine Oral Liquid Suspension And Use Thereof |
May, 2040
(14 years from now) | Active |
| US11612566 | Lamotrigine Oral Liquid Suspension And Use Thereof |
May, 2040
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Subvenite's patents.
Latest Legal Activities on Subvenite's Patents
Given below is the list of recent legal activities going on the following patents of Subvenite.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 28 Mar, 2023 | US11612566 |
| Patent Issue Date Used in PTA Calculation | 28 Mar, 2023 | US11612566 |
| Issue Notification Mailed | 08 Mar, 2023 | US11612566 |
| Patent Issue Date Used in PTA Calculation | 07 Mar, 2023 | US11596634 |
| Recordation of Patent Grant Mailed | 07 Mar, 2023 | US11596634 |
| Dispatch to FDC | 24 Feb, 2023 | US11612566 |
| Application Is Considered Ready for Issue | 24 Feb, 2023 | US11612566 |
| Issue Fee Payment Received | 20 Feb, 2023 | US11612566 |
| Issue Notification Mailed | 15 Feb, 2023 | US11596634 |
| Application Is Considered Ready for Issue | 02 Feb, 2023 | US11596634 |
US patents provide insights into the exclusivity only within the United States, but
Subvenite is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Subvenite's family patents as well as insights into
ongoing legal events
on those patents.
Subvenite's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Subvenite's generic launch date based on the expiry of its last outstanding patent is estimated to be May 29, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Subvenite Generic API suppliers:
Lamotrigine is the generic name for the brand Subvenite. 40 different companies have already filed for the generic of Subvenite, with Ph Health having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Subvenite's generic
Alternative Brands for Subvenite
There are several other brand drugs using the same active ingredient (Lamotrigine) as Subvenite. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Glaxosmithkline Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Lamotrigine, Subvenite's active ingredient. Check the complete list of approved generic manufacturers for Subvenite
About Subvenite
Subvenite is a drug owned by Owp Pharmaceuticals Inc. Subvenite uses Lamotrigine as an active ingredient. Subvenite was launched by Owp in 2025.
Approval Date:
Subvenite was approved by FDA for market use on 16 September, 2025.
Active Ingredient:
Subvenite uses Lamotrigine as the active ingredient. Check out other Drugs and Companies using Lamotrigine ingredient
Dosage:
Subvenite is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/ML | SUSPENSION | Prescription | ORAL |